Pharmacokinetics of amikacin in febrile neutropenic pediatric patients with acute lymphoblastic leukemia

Abstract

The pharmacokinetics of amikacin was investigated in six oncohematologic pediatric patients who experienced neutropenia (<1,000/mm3) and fever (>38°C) induced by cancer chemotherapy. The concentration of amikacin in serum was determined by fluorescence polarization immunoassay method using Abbott TDx system. Pharmacokinetic parameters were estimated with the help of computer software, PK II. Peak serum concentration of 36.30±4.03 ug/ml was observed. The values for AUCo, AUMCo, and MRT were concluded to be 76.20$\pm$6.30 ug.hr/ml, 190.26±31.61 $\mu$g.hr2/ml and 2.15$\pm$0.62 hrs, respectively. The t1/2$\alpha$, t1/2elim, Cl and Vd were 0.0410.02 hr, 1.76$\pm$0.55 hr, 18.85$\pm$5.11 ml/min and 0.191$\pm$0.11 l/kg, respectively. When the present values were compared with the literature-cited values in normal as well as in diseased populations, some similarities and differences were observed. Due to polemical values reported for normal population the modifications in amikacin pharmacokinetics in pediatric cancer patients has left inconclusive. Further appraisal is required to make a firm conclusion.

Özet